486 related articles for article (PubMed ID: 12688309)
1. Purine nucleoside analogues in the treatment of myleoid leukemias.
Robak T
Leuk Lymphoma; 2003 Mar; 44(3):391-409. PubMed ID: 12688309
[TBL] [Abstract][Full Text] [Related]
2. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
3. Combination regimen of cladribine (2-chlorodeoxyadenosine), cytarabine and G-CSF (CLAG) as induction therapy for patients with relapsed or refractory acute myeloid leukemia.
Robak T; Wrzesień-Kuś A; Lech-Marańda E; Kowal M; Dmoszyńska A
Leuk Lymphoma; 2000 Sep; 39(1-2):121-9. PubMed ID: 10975390
[TBL] [Abstract][Full Text] [Related]
4. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
6. The influence of farnesyl protein transferase inhibitor R115777 (Zarnestra) alone and in combination with purine nucleoside analogs on acute myeloid leukemia progenitors in vitro.
Korycka A; Smolewski P; Robak T
Eur J Haematol; 2004 Dec; 73(6):418-26. PubMed ID: 15522064
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
8. Fludarabine, cytarabine, G-CSF and idarubicin (FLAG-IDA) for the treatment of relapsed or poor risk childhood acute leukemia.
Yalman N; Sarper N; Devecioğlu O; Anak S; Eryilmaz E; Can M; Yenilmez H; Ağaoğlu L; Gedikoğlu G
Turk J Pediatr; 2000; 42(3):198-204. PubMed ID: 11105617
[TBL] [Abstract][Full Text] [Related]
9. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
10. The effect of cyclosporin A used alone and in combination with either 2-chlorodeoxyadenosine or fludarabine on normal and chronic myelogenous leukemia progenitors in vitro.
Korycka A; Robak T
Arch Immunol Ther Exp (Warsz); 2003; 51(1):61-7. PubMed ID: 12691305
[TBL] [Abstract][Full Text] [Related]
11. FLAG-IDA in the treatment of refractory/relapsed acute leukaemias: single centre study.
Hashmi KU; Khan B; Ahmed P; Raza S; Hussain I; Mahmood A; Iqbal H; Malik HS; Anwar M
J Pak Med Assoc; 2005 Jun; 55(6):234-8. PubMed ID: 16045091
[TBL] [Abstract][Full Text] [Related]
12. FLAG (fludarabine + high-dose cytarabine + G-CSF): an effective and tolerable protocol for the treatment of 'poor risk' acute myeloid leukemias.
Visani G; Tosi P; Zinzani PL; Manfroi S; Ottaviani E; Testoni N; Clavio M; Cenacchi A; Gamberi B; Carrara P
Leukemia; 1994 Nov; 8(11):1842-6. PubMed ID: 7526088
[TBL] [Abstract][Full Text] [Related]
13. [Current and new therapeutic strategies in acute myeloid leukemia].
Naito K; Ohnishi K
Gan To Kagaku Ryoho; 2005 Mar; 32(3):292-6. PubMed ID: 15791811
[TBL] [Abstract][Full Text] [Related]
14. Engraftment of allogeneic hematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing graft-versus-leukemia without myeloablative therapy.
Giralt S; Estey E; Albitar M; van Besien K; Rondón G; Anderlini P; O'Brien S; Khouri I; Gajewski J; Mehra R; Claxton D; Andersson B; Beran M; Przepiorka D; Koller C; Kornblau S; Kørbling M; Keating M; Kantarjian H; Champlin R
Blood; 1997 Jun; 89(12):4531-6. PubMed ID: 9192777
[TBL] [Abstract][Full Text] [Related]
15. IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial.
Fleischhack G; Hasan C; Graf N; Mann G; Bode U
Br J Haematol; 1998 Aug; 102(3):647-55. PubMed ID: 9722289
[TBL] [Abstract][Full Text] [Related]
16. Treatment of relapse after allogeneic bone marrow transplantation with reduced intensity conditioning (FLAG +/- Ida) and second allogeneic stem cell transplant.
Pawson R; Potter MN; Theocharous P; Lawler M; Garg M; Yin JA; Rezvani K; Craddock C; Rassam S; Prentice HG
Br J Haematol; 2001 Dec; 115(3):622-9. PubMed ID: 11736947
[TBL] [Abstract][Full Text] [Related]
17. Present status of purine analogs in the therapy of chronic lymphocytic leukemias.
Bergmann L
Leukemia; 1997 Apr; 11 Suppl 2():S29-34. PubMed ID: 9178835
[TBL] [Abstract][Full Text] [Related]
18. Mito-flag as salvage therapy for relapsed and refractory acute myeloid leukemia.
Hänel M; Friedrichsen K; Hänel A; Herbst R; Morgner A; Neser S; Nicklisch M; Teich M; Ehninger G; Fiedler F
Onkologie; 2001 Aug; 24(4):356-60. PubMed ID: 11574763
[TBL] [Abstract][Full Text] [Related]
19. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of acute myeloid leukemia relapsing after autologous stem cell transplantation.
Ferrara F; Melillo L; Montillo M; Leoni F; Pinto A; Mele G; Mirto S
Ann Hematol; 1999 Aug; 78(8):380-4. PubMed ID: 10460353
[TBL] [Abstract][Full Text] [Related]
20. High efficacy of fludarabine-containing therapy (FLAG-FLANG) in poor risk acute myeloid leukemia.
Clavio M; Carrara P; Miglino M; Pierri I; Canepa L; Balleari E; Gatti AM; Cerri R; Celesti L; Vallebella E; Sessarego M; Patrone F; Ghio R; Damasio E; Gobbi M
Haematologica; 1996; 81(6):513-20. PubMed ID: 9009438
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]